1. Discovery of β2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. Tonia Aristotelous, Seungkirl Ahn, Arun K. Shukla, Bryan L. Roth,  Andrew L. Hopkins, Robert J. Lefkowitz, Iva Navratilova et al. ACS Med. Chem. Lett., 2013, 4 (10), 1005–1010

  2. Biosensor based approach to the identification of protein kinase ligands with dual site modes of action. Iva Navratilova et al. J. Biomolecular Screening (2011), J Biomol Screen (2012) 17 (2), 183-193

  3. Emerging role of surface plasmon resonance in fragment-based drug discovery. Iva Navratilova and Andrew L. Hopkins, Future Medicinal Chemistry (2011), 3(14), 1809-1820

  4. Screening for GPCR Ligands Using Surface Plasmon Resonance. Iva Navratilova, Jeremy Besnard and Andrew L. Hopkins ACS Med Chem Letters (2011) 2 (7), 549-554

  5. Fragment Screening by Surface Plasmon Resonance.  Iva Navratilova and Andrew L. Hopkins, ACS Med Chem Letters (2010) 1(1), 44-48

  6. Thermodynamic benchmark study using Biacore technology. Iva Navratilova et al. Analytical Biochem (2007), 364(1), 67-77

  7. Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology. Iva Navratilova et al. Analytical Biochem (2006) 355(1), 132-139

  8. A biosensor-based approach toward purification and crystallization of G protein-coupled receptors. Iva Navratilova et al. Analytical Biochem, (2006), 353(2), 278-283

  9. Measuring long association phases using Biacore. Iva Navratilova et al. Analytical Biochem (2005), 344, 295-297

  10. Solubilization, stabilization and purification of chemokine receptors using biosensor technology. Iva Navratilova et al., Analytical Biochem (2005) 339, 271-281

  11. Ligand Efficiency: a useful metric for lead selection. Andrew L. Hopkins, Colin R. Groom and Alex Alex, Drug Discovery Today (2004), 9(10), 430-431